Loading...
Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors
Veliparib (ABT‐888) is a potent, orally bioavailable poly(ADP‐ribose) polymerase‐1 and ‐2 inhibitor. This phase 1 study evaluated the tolerability, pharmacokinetic profile, safety, and preliminary antitumor activity of single‐agent veliparib in Japanese patients with advanced solid tumors. Eligible...
Na minha lista:
| Udgivet i: | Cancer Sci |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5581522/ https://ncbi.nlm.nih.gov/pubmed/28665051 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13307 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|